Charles Schwab Investment Management Inc Kinnate Biopharma Inc. Transaction History

Charles Schwab Investment Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$2.33 - $6.84 $113,557 - $333,361	-48,737 Reduced 34.56%	92,267 $279,000
Q1 2023 May 11, 2023	SELL	$3.46 - $7.98 $27,842 - $64,215	-8,047 Reduced 5.4%	141,004 $881,000
Q4 2022 Feb 13, 2023	BUY	$5.26 - $12.19 $11,871 - $27,512	2,257 Added 1.54%	149,051 $909,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $32,232 - $51,519	3,269 Added 2.28%	146,794 $1.76 Million
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $83,520 - $146,133	11,241 Added 8.5%	143,525 $1.81 Million

Q1 2022 May 13, 2022	SELL	$7.73 - $17.99 $19,216 - $44,723	-2,486 Reduced 1.84%	132,284 $1.49 Million
Q4 2021 Feb 11, 2022	BUY	$16.5 - $25.48 $23,628 - $36,487	1,432 Added 1.07%	134,770 $2.39 Million
Q3 2021 Nov 16, 2021	BUY	$17.81 - $24.87 $770,959 - $1.08 Million	43,288 Added 48.07%	133,338 $3.07 Million
Q2 2021 Aug 16, 2021	BUY	$22.19 - $31.55 $31,265 - $44,453	1,409 Added 1.59%	90,050 $2.1 Million
Q1 2021 May 17, 2021	BUY	$26.99 - $40.0 $2.39 Million - $3.55 Million	88,641 New	88,641 $2.76 Million

32.9M

94.7K

802K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.